Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

Bone

Volumn 31, Issue 5, 2002, Pages 620-625

  Eriksen, E F ^a   Melsen, F ^a   Sod, E ^b   Barton, I ^b   Chines, Arkadi ^b,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c NONE   (United States)

Author keywords

Bisphosphonates; Bone remodeling; Histology; Histomorphometry; Osteoporosis; Postmenopausal; Risedronate

Indexed keywords

PLACEBO; RISEDRONIC ACID; DRUG DERIVATIVE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILIAC BONE; MAJOR CLINICAL STUDY; MORPHOMETRICS; OSSIFICATION; OSTEOMALACIA; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; BONE DEVELOPMENT; BONE REMODELING; COMPARATIVE STUDY; MIDDLE AGED; NONPARAMETRIC TEST; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; SPINE FRACTURE;

AGED; AGED, 80 AND OVER; BONE REMODELING; BONE RESORPTION; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; STATISTICS, NONPARAMETRIC;

EID: 0036862022     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00869-4     Document Type: Article

References (26)

1. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 27:2000;687-694.
2. Boyce R.W., Paddock C.L., Gleason J.R., Sietsema W.K., Eriksen E.F. The effects of risedronate on canine cancellous bone remodeling Three-dimensional kinetic reconstruction of the remodeling site . J Bone Miner Res. 10:1995;211-221.
3. Bravenboer N., Papapoulos E., Holzmann P., Hamdy N., Netelenbos J., Lips P. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteopor Int. 9:1999;489-493.
4. Chavassieux P., Arlot M., Reda C., Wei L., Yates J., Meunier P. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 100:1997;1475-1480.
5. Cohen S., Levy R.M., Keller M., Boling E., Emkey R.D., Greenwald M., Zizic T.M., Wallach S., Sewell K.L., Lukert B.P., et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum. 42:1999;2309-2318.
6. Cohen-Solal M.E., Roux C., Valentin-Opran A., Dougados M., Amor B., DeVernejoul M.C. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone. 14:1993;505-509.
7. Eastell R., Barton I., Hannon R.A., Garnero P., Chines A., Pack S., Delmas P.D. Antifracture efficacy of risedronate Prediction by change in bone resorption markers . J Bone Miner Res. 16:(Suppl. 1):2001;S163.
8. Eriksen E.F. Normal and pathological remodeling of human trabecular bone Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease . Endocrine Rev. 7:1986;379-408.
9. Garnero P., Hausherr E., Chapuy M., Marcelli C., Grandjean H., Muller C., Cormier C., Breart G., Meunier P., Delmas P. Markers of bone resorption predict hip fracture in elderly women. The EPIDOS prospective study. J Bone Miner Res. 11:1996;1531-1538.
10. Harris S.T., Watts N.B., Genant H.K., McKeever C.K., Hangartner T., Keller M., Chesnut C.H. III, Brown J., Eriksen E., Hoseyni M.S., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA. 282:1999;1344-1352.
11. Hauge E., Mosekilde L., Melsen F., Frydenberg M. How many patients are needed? Variation and design considerations in bone histomorphometry. Bone. 28:2001;556-562.
12. Heaney R.P., Yates A.J., Santora A.C. II. Bisphosphonate effects and the remodeling transient. J Bone Miner Res. 12:1997;1143-1151.
13. Hosking D., Sorensen O., Mulder H., Adami S., Pack S., Wenderoth D., Reginister J.-Y. Sustained fracture benefit with 5 years of risedronate in postmenopausal women. Bone. 28:(Suppl.):2001;S229.
14. Khastgir G., Studd J., Holland N., Alaghband-Zadeh J., Fox S., Chow J. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis Histomorphometric evidence in a longitudinal study . J Clin Endocrinol Metab. 86:2001;289-294.
15. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 15:2000;613-620.
16. McClung M.R., Geusen P., Miller P.D., Zippel H., Bensen W.G., Roux C., Adami S., Fogelman I., Diamond T., Eastell R., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344:2001;333-340.
17. Melton L. III, Khosla S., Atkinson E., O'Fallon W., Riggs B. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 12:1997;1083-1091.
18. Miller P.D., Brown J.P., Siris E.S., Hoseyni M.S., Axelrod D.W., Bekker P.J. A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone. Am J Med. 106:1999;513-520.
19. Parfitt A.M., Mathews C.H., Villanueva A.R., Kleerekoper M., Frame B., Rao D.S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 72:1983;1396-1409.
20. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R. Bone histomorphometry Standardization of nomenclature, symbols, and units . J Bone Miner Res. 2:(6):1987;595-610.
21. Reginster J.-Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., Lund B., Ethgen D., Pack S., Roumagnac I., Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteopor Int. 11:2000;83-91.
22. Reid D.M., Hughes R.A., Laan R., Sacco-Gibson N.A., Wenderoth D.H., Adami S., Eusebio R.A., Devogelaer J.-P. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women A randomized trial . J Bone Miner Res. 15:2000;1006-1013.
23. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88:2000;2961-2974.
24. Roux C., Ravaud P., Cohen-Solal M., DeVernejoul M.C., Guillemant S., Cherruau B., Delmas P., Dougados M., Armor B. Biologic, histologic, and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 15:1994;41-49.
25. Sietsema W.K., Ebetino F.H., Salvagno A.M., Bevan J.A. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 15:1989;389-396.
26. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., Laan R.F., Doherty S.M., Maricic M., Rosen C., Brown J., Barton I., Chines A.A. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 67:2000;277-285.